KRASG12C inhibition in colorectal cancer.

Abstract

For years, patients with metastatic colorectal cancer were considered and treated as a single biological entity. Since the association between activated RAS mutations and low efficacy of anti-epidermal growth factor receptor (EGFR) therapy became evident, it has been recommended that all patients with metastatic colorectal cancer are routinely tested for RAS mutations. Mutations in RAS are one the most frequent oncogenic drivers in human cancers, with a frequency of nearly 50% in patients with metastatic colorectal cancer dominated by mutations in KRAS codon 12, but KRASG12C is only present in 3% of patients with metastatic colorectal cancer.